Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Aprea Therapeutics Inc (APRE)

22 + Investors. Track Smart Money conviction in APRE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
48%

Smart Money Signals — APRE

Based on 22 hedge funds · latest filing: 2026 Q1 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
📊

High ownership — 85% of 3.0Y peak

85% of all-time peak
22 funds currently hold this stock — 85% of the 3.0-year high of 26 funds (reached 2025 Q1). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 15% fewer funds vs a year ago

fund count last 6Q
4 fewer hedge funds hold APRE compared to a year ago (-15% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟠

More sellers than buyers — 48% buying

11 buying12 selling
Last quarter: 12 funds reduced or exited vs 11 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~7 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 1 → 2 → 5 → 7. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 23% medium ■ 27% new
11 out of 22 hedge funds have held APRE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~7 new funds/quarter

2 → 1 → 2 → 5 → 7 new funds/Q
New funds entering each quarter: 1 → 2 → 5 → 7. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 36% veterans, 27% new entrants

■ 36% veterans ■ 36% 1-2yr ■ 27% new
Of 22 current holders: 8 (36%) held 2+ years, 8 held 1–2 years, 6 (27%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 10% AUM from top-100

10% from top-100 AUM funds
6 of 22 holders rank in the top 100 by AUM, but together hold only 10% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.0
out of 10
Low Exit Risk
Exit risk score 3.0/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — APRE

In 2026 Q1, 11 hedge funds were net buyers of APRE (7 opened a new position, 4 added to an existing one), while 12 reduced or exited (5 trimmed, 7 sold completely) — a 48% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 22.

Hedge Fund Ownership: APRE

How many hedge funds hold APRE — quarterly history vs. share price
Quarterly hedge fund ownership of APRE vs. share price

Market Analysis: APRE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: APRE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Aprea Therapeutics Inc (APRE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much APRE has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 83d ago
APRE
+2.6%
XLV
+710.5%

APRE outperformed XLV by -707.9% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 38d ago
APRE
-15.8%
XLV
+697.4%

Since the filing became public, APRE outperformed XLV by -713.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

3 top-rated funds 0 high-conviction
Consensus
2.6
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: APRE
22 + Investors

Track Smart Money conviction in APRE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 22 22 -
13F Shares 2M 2M 32.37%
Total Value $2M $1M 18.39%
New Positions 7 5 +2
Increased Positions 4 5 -1
Closed Positions 7 6 +1
Reduced Positions 5 6 -1
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: APRE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

22 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in APRE. Verified SEC 13F-HR filings.

QUARTER:
Top 21 APRE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 AIGH Capital Management LLC 0.11% 1,015,541 $775K
2 Scientech Research LLC 0.04% 60,281 $46K
3 Sphera Funds Management LTD. 0.03% 270,000 $206K
4 Vestal Point Capital, LP 0.01% 350,000 $267K
5 Nantahala Capital Management, LLC 0.01% 205,760 $157K
6 Two Sigma Securities, LLC 0.00% 13,500 $10K
7 Tower Research Capital LLC (TRC) 0.00% 5,127 $4K
8 WealthCollab, LLC 0.00% 158 —
9 Renaissance Technologies LLC 0.00% 25,100 $19K
10 BNP Paribas Financial Markets 0.00% 39,817 $30K
11 HighTower Advisors, LLC 0.00% 13,864 $11K
12 Vanguard Fiduciary Trust Co 0.00% 38,464 $29K
13 LPL Financial LLC 0.00% 21,052 $16K
14 Susquehanna International Group, LLP 0.00% 13,018 $10K
15 Morgan Stanley 0.00% 22,330 $17K
16 Group One Trading LLC 0.00% 577 —
17 Vanguard Capital Management LLC 0.00% 19,622 $15K
18 Osaic Holdings, INC. 0.00% 295 —
19 SBI Securities Co., Ltd. 0.00% 16 —
20 UBS Group AG 0.00% 2,153 $2K
21 BlackRock, Inc. 0.00% 8,504 $6K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Aprea Therapeutics Inc (APRE)

What does the Smart Money Trend signal show for APRE?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for APRE?

More sellers than buyers — 48% buying: Last quarter: 12 funds reduced or exited vs 11 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for APRE holders?

Smaller funds dominant — 10% AUM from top-100: 6 of 22 holders rank in the top 100 by AUM, but together hold only 10% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held APRE?

50% of holders stayed for 2+ years: 11 out of 22 hedge funds have held APRE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Aprea Therapeutics Inc (APRE) following the 2026 Q1 hedge fund 13F filings?

As of today, APRE has moved -15.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +697.4% for the XLV sector ETF — an outperformance of -713.2%. Since the quarter end (March 31, 2026), APRE has gained +2.6% vs +710.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →